Novo Nordisk’s Norditropin

Norditropin was developed by Danish pharmaceutical company Novo Nordisk. It is available for sale in the U.S. and Europe through Novo Nordisk and in Japan through Yamanouchi. Norditropin is manufactured by Protein Secretion technology. In the U.S., the Food and Drug Administration (FDA — an agency that regulates the medicine market) has approved Norditropin for treatment of pediatric and adult GHD, growth failure in females with Turner’s syndrome, growth failure caused by chronic renal disease, and SGA and IUGR. Norditropin is available in lyophilized powder form as well as a pre-mixed formula. Delivery options include both a pen and syringe.